FDG-PET appears promising for predicting prognosis of patients with inoperable NSCLC
The prognosis for patients with stage II and III inoperable non-small cell lung cancer (NSCLC) is poor, with only about 15 percent of patients surviving at five years post-treatment for the disease. While new treatment strategies ...
Oct 5, 2011
0
0